AR015984A1 - Uso de antagonistas d1/d5, agonistas parciales d1/d5, mezclas de los mismos para la preparacion de un medicamento para reducir las ansias del consumo dealimento o sustancias adictivas en mamiferos y un kit que los comprende - Google Patents

Uso de antagonistas d1/d5, agonistas parciales d1/d5, mezclas de los mismos para la preparacion de un medicamento para reducir las ansias del consumo dealimento o sustancias adictivas en mamiferos y un kit que los comprende

Info

Publication number
AR015984A1
AR015984A1 ARP980105373A ARP980105373A AR015984A1 AR 015984 A1 AR015984 A1 AR 015984A1 AR P980105373 A ARP980105373 A AR P980105373A AR P980105373 A ARP980105373 A AR P980105373A AR 015984 A1 AR015984 A1 AR 015984A1
Authority
AR
Argentina
Prior art keywords
reduce
antagonist
food consumption
antagonists
kit
Prior art date
Application number
ARP980105373A
Other languages
English (en)
Spanish (es)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR015984A1 publication Critical patent/AR015984A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP980105373A 1997-10-28 1998-10-27 Uso de antagonistas d1/d5, agonistas parciales d1/d5, mezclas de los mismos para la preparacion de un medicamento para reducir las ansias del consumo dealimento o sustancias adictivas en mamiferos y un kit que los comprende AR015984A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95921397A 1997-10-28 1997-10-28

Publications (1)

Publication Number Publication Date
AR015984A1 true AR015984A1 (es) 2001-05-30

Family

ID=25501785

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980105373A AR015984A1 (es) 1997-10-28 1998-10-27 Uso de antagonistas d1/d5, agonistas parciales d1/d5, mezclas de los mismos para la preparacion de un medicamento para reducir las ansias del consumo dealimento o sustancias adictivas en mamiferos y un kit que los comprende

Country Status (16)

Country Link
EP (1) EP1043980A2 (pt)
JP (1) JP2001520989A (pt)
KR (1) KR20010031470A (pt)
CN (1) CN1283116A (pt)
AR (1) AR015984A1 (pt)
AU (1) AU1110099A (pt)
BR (1) BR9814830A (pt)
CA (1) CA2308453A1 (pt)
CO (1) CO4970824A1 (pt)
HU (1) HUP0100115A2 (pt)
IL (1) IL135659A0 (pt)
NO (1) NO20002149L (pt)
PE (1) PE122299A1 (pt)
SK (1) SK5812000A3 (pt)
WO (1) WO1999021540A2 (pt)
ZA (1) ZA989786B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410527B1 (en) * 1998-03-02 2002-06-25 Schering Corporation Method of treating obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders, and autism
PE20000333A1 (es) * 1998-03-02 2000-05-13 Schering Corp Metodo para tratar desordenes compulsivos obsesivos, desordenes somatoformes, desordenes disociativos, desordenes al comer, desordenes de control de impulso y autismo
US6890951B2 (en) 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
US6541520B1 (en) 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US6395783B1 (en) 2000-10-23 2002-05-28 Brookhaven Science Associates, Llc Treatment of PCP addiction and PCP addiction-related behavior
US6462084B1 (en) 2001-05-14 2002-10-08 Brookhaven Science Associates, Llc Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
DE60231896D1 (de) 2001-11-05 2009-05-20 Krele Pharmaceuticals Llc Zusammensetzungen und verfahren zur erhöhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus
JP6355921B2 (ja) 2010-09-01 2018-07-11 トニックス ファーマスーティカルズ, インコーポレイテッドTONIX Pharmaceuticals, Inc. コカイン嗜癖の治療
AU2013289922B2 (en) 2012-07-12 2016-12-15 Psyadon Pharmaceuticals, Inc. Fused benzazepines for treatment of Tourette's Syndrome
SMT202000398T1 (it) * 2013-10-18 2020-09-10 Emalex Biosciences Inc Benzazepine fuse per il trattamento della balbuzie
CN110327350B (zh) * 2019-07-11 2021-02-23 温州医科大学 多巴胺d1受体拮抗剂sch39166在作为制备治疗眼部病理性血管新生药物的应用
CN110833621A (zh) * 2019-12-06 2020-02-25 中国医科大学 多巴胺受体1拮抗剂在制备治疗对氯胺酮致小鼠类精神分裂症药物上的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607967A (en) * 1994-10-27 1997-03-04 Merck & Co., Inc. Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid
AU3408097A (en) * 1996-06-06 1998-01-05 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and seroto nin agonists

Also Published As

Publication number Publication date
WO1999021540B1 (en) 1999-10-28
SK5812000A3 (en) 2000-12-11
HUP0100115A2 (hu) 2001-06-28
JP2001520989A (ja) 2001-11-06
NO20002149L (no) 2000-06-26
WO1999021540A3 (en) 1999-09-02
CA2308453A1 (en) 1999-05-06
AU1110099A (en) 1999-05-17
ZA989786B (en) 1999-04-28
NO20002149D0 (no) 2000-04-27
EP1043980A2 (en) 2000-10-18
PE122299A1 (es) 1999-12-04
CN1283116A (zh) 2001-02-07
IL135659A0 (en) 2001-05-20
KR20010031470A (ko) 2001-04-16
WO1999021540A2 (en) 1999-05-06
CO4970824A1 (es) 2000-11-07
BR9814830A (pt) 2000-10-03

Similar Documents

Publication Publication Date Title
AR015984A1 (es) Uso de antagonistas d1/d5, agonistas parciales d1/d5, mezclas de los mismos para la preparacion de un medicamento para reducir las ansias del consumo dealimento o sustancias adictivas en mamiferos y un kit que los comprende
Doogan et al. Sertraline: a new antidepressant.
Cardenas et al. 5HT4 receptors couple positively to tetrodotoxin-insensitive sodium channels in a subpopulation of capsaicin-sensitive rat sensory neurons
Ma et al. Glucagon stimulates exocytosis in mouse and rat pancreatic α-cells by binding to glucagon receptors
ES2151672T3 (es) Composiciones de rapida disolucion oral para agonistas de dopamina.
Hassell et al. Drug-induced gingival overgrowth: old problem, new problem
ES2120067T3 (es) Metodos para inducir tolerancia de celulas t antigeno especifica.
FI960727A0 (fi) Neurokiniiniantagonisteina käyttökelpoiset heterosyklit
CY1110260T1 (el) Στερεες φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν εναν αγωνιστη υποδοχεα s1p και μια αλκοολη σακχαρων
EA200100541A1 (ru) Фармацевтическая композиция с модифицированным высвобождением сенсибилизатора к инсулину и других антидиабетических агентов
SV2002000969A (es) Composicion parenteral reconstituible
AR038202A1 (es) Compuestos de indazol utiles como inhibidores de la proteina quinasa
Holladay et al. Developmental immunotoxicology
Sanchez et al. The selective σ2 ligand Lu 28-179 has an antidepressant-like profile in the rat chronic mild stress model of depression
Javanmard Khameneh et al. The inflammasome adaptor ASC intrinsically limits CD4+ T-cell proliferation to help maintain intestinal homeostasis
AR022839A1 (es) Antagonistas de la integrina alfavbeta3 en combinacion con agentes quimioterapeuticos
CR6581A (es) Pirrolcarboxamidas fundido, receptores cerebrales gaba
Call et al. In vivo enhancement of peptide display by MHC class II molecules with small molecule catalysts of peptide exchange
ES2187489T3 (es) Composiciones farmaceuticas a base de diclofenac.
AR024232A1 (es) Bromhidrato de eletriptan monohidratado, composicion farmaceutica, su uso en la preparacion de medicamentos y procedimiento para su preparacion
EA199901116A1 (ru) Композиция, включающая 5-[4-[2-(n-метил-n-2-пиридил)-амино)этокси]бензил]тиазолидин-2,4-дион
AR004093A1 (es) El uso de una proteina derivada de una quimioquina de mamifero y un medicamento util para movilizar celulas tronco hematopoyeticas.
NO944214L (no) Farmasöytiske preparater for rektal administrering, inneholdende alkylsulfonamider som er HT1-agonister
PE20040670A1 (es) Nuevas composiciones farmaceuticas que contienen ambroxol y yoduro de isopropamida
AU621705B2 (en) Evaluative means for detecting inflammatory reactivity

Legal Events

Date Code Title Description
FB Suspension of granting procedure